Covid, FDA and vaccines
Digest more
SHELTON, CT / ACCESS Newswire / May 22, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE Amer.:NNVC ) (the “Company”), comments on the new COVID Vaccine policy adopted by the US FDA. The new FDA COVID Vaccine Booster Shots policy [1] is based on the findings that the groups that benefit from repeat
The agency said it would approve new versions of the vaccine only for adults 65 years of age and older as well as for people with one or more risk factors for severe COVID-19 outcomes. These risk factors include medical conditions such as asthma, cancer, chronic kidney disease, heart disease and diabetes.
Amid a growing distrust of vaccines and the medical community, there’s also been a growing divide in the Make America Healthy Again initiative.
Health agencies working under Robert F. Kennedy Jr. are making changes to the nation's decades-old system for approving and recommending vaccines.
Expert advisors for the Food and Drug Administration met Thursday to discuss which virus strain this year's updated COVID-19 vaccines should target. The advisors have been meeting around this time each year for such a strain selection,